{"filing":{"accession_number":"0001193125-26-347400","cik":"0001789972","ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"cgem-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526347400/cgem-20260812.htm"},"events":[{"id":27392,"run_id":24960,"accession_number":"0001193125-26-347400","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Cullinan announced that its Phase 3 REZILIENT3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis for zipalertinib in combination with chemotherapy for EGFR exon 20 insertion NSCLC, demonstrating statistically significant and clinically meaningful improvement with manageable safety. The company plans to pursue U.S. regulatory approval based on these positive results, representing a material clinical development milestone for its lead program.","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28911,"accession_number":"0001193125-26-347400","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that Cullinan's Phase 3 REZILIENT3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis for zipalertinib in combination with chemotherapy for EGFR exon 20 insertion NSCLC. This is a material clinical development milestone that supports potential regulatory approval and commercialization, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-named event type. The positive trial outcome is a significant operational/clinical milestone that would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:05:58.661718+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28912,"accession_number":"0001193125-26-347400","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the REZILIENT3 Phase 3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis, with statistically significant and clinically meaningful improvement in the zipalertinib-containing arm and manageable safety. The companies plan to pursue U.S. regulatory approval based on these results. This is a material clinical milestone for a biopharmaceutical company's lead program, affecting investor assessment of the registrant's pipeline and regulatory prospects, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other named event types—it is a positive clinical development and regulatory milestone that is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:05:58.661718+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28911,"accession_number":"0001193125-26-347400","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that Cullinan's Phase 3 REZILIENT3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis for zipalertinib in combination with chemotherapy for EGFR exon 20 insertion NSCLC. This is a material clinical development milestone that supports potential regulatory approval and commercialization, but it is not a financial result (earnings_release), M\u0026A activity, or other specifically-named event type. The positive trial outcome is a significant operational/clinical milestone that would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:05:58.661718+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-08-12"},{"id":28912,"accession_number":"0001193125-26-347400","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces that the REZILIENT3 Phase 3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis, with statistically significant and clinically meaningful improvement in the zipalertinib-containing arm and manageable safety. The companies plan to pursue U.S. regulatory approval based on these results. This is a material clinical milestone for a biopharmaceutical company's lead program, affecting investor assessment of the registrant's pipeline and regulatory prospects, but does not fit the specific categories of earnings release, exec changes, M\u0026A, impairment, or other named event types—it is a positive clinical development and regulatory milestone that is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:05:58.661718+00:00","company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","filing_date":"2026-08-12"}]}